No profile data available.
Abeona Therapeutics Inc. (ABEO) is a healthcare company in the skin treatment pharmaceuticals industry, based in Cleveland, United States, with about 136 full-time employees.
It reported revenue of $5.82 million for fiscal year 2025, and net income of $71.18 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $11.38 million, up 2745.0% from a year before. Its market capitalization was $263.91 million as of December 4, 2025.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of December 4, 2025.
, a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is pz-cel, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa.
Abeona Therapeutics reported $5.82 million in revenue for fiscal year 2025. In Q2 2026 revenue was $11.38 million.
$263.91 million as of December 4, 2025.
Listed companies of a similar size in the same industry (skin treatment pharmaceuticals) include Aclaris Therapeutics, Inc. (ACRS), Evolus, Inc. (EOLS), Avalo Therapeutics, Inc. (AVTX), Q32 Bio Inc. (QTTB).